Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EDP2939 in moderate plaque psoriasis
2022-001631-82Phase 2Completed
- Sponsor
- Evelo Biosciences
- Start
- Oct 2022
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in plaque psoriasis comparing EDP2939 with Placebo (2 arms). Primary endpoint: PASI-50 response at Week 16. Started Oct 2022; status: completed.
02
Drugs
EDP2939
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on 2022-001631-82.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-001631-82.